Ranitidine tablets IP 300 mg are a medication used to reduce stomach acid production. This drug is a histamine H2-receptor antagonist and is prescribed for conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome [1]. The "IP" in Ranitidine tablets IP indicates they comply with the Indian Pharmacopoeia standards for quality and purity [2].
What is the typical dosage for Ranitidine 300 mg tablets?
The usual dosage for Ranitidine 300 mg tablets for adults is one tablet taken orally once or twice a day. The specific dosing regimen can vary based on the condition being treated and the patient's response, and it should be determined by a healthcare professional [3].
Why was Ranitidine withdrawn from the market?
Ranitidine was withdrawn from the market in many countries, including the United States and India, due to the detection of N-Nitrosodimethylamine (NDMA), a probable human carcinogen, in ranitidine products. The U.S. Food and Drug Administration (FDA) requested its withdrawal in April 2020 after finding unacceptable levels of NDMA that increased over time and upon storage [4][5].
What are the alternatives to Ranitidine for acid reduction?
Following the withdrawal of ranitidine, alternative medications for reducing stomach acid are available. These include other histamine H2-receptor antagonists like famotidine and cimetidine, as well as proton pump inhibitors (PPIs) such as omeprazole, lansoprazole, and pantoprazole [4][6].
What are the safety concerns associated with Ranitidine?
The primary safety concern that led to the market withdrawal of ranitidine was the presence of NDMA, a potential carcinogen. Studies indicated that NDMA could form in ranitidine tablets over time, and the levels were found to be higher than what is considered safe [4][5].